scholarly article | Q13442814 |
P50 | author | Georgia Chenevix-Trench | Q17517031 |
Stephen Chanock | Q27662321 | ||
Pamela J. Thompson | Q116977453 | ||
Hoda Anton-Culver | Q28052887 | ||
Montserrat García-Closas | Q28356305 | ||
Jolanta Lissowska | Q28606996 | ||
Argyrios Ziogas | Q30831638 | ||
Estrid Høgdall | Q30831658 | ||
Susanne Krüger Kjaer | Q38297251 | ||
Penelope M. Webb | Q41235493 | ||
Alice S. Whittemore | Q42423380 | ||
Robert Vierkant | Q42681243 | ||
Australian Ovarian Cancer Study Group | Q42790423 | ||
Susan J. Ramus | Q45906365 | ||
Shelley S. Tworoger | Q46915135 | ||
Jan Blaakær | Q52562626 | ||
Jonathan Beesley | Q56524232 | ||
Louise A. Brinton | Q58623846 | ||
Douglas F. Easton | Q59812154 | ||
David Van Den Berg | Q60686183 | ||
Paul D P Pharoah | Q61822938 | ||
Joellen M Schildkraut | Q61822968 | ||
Julie M. Cunningham | Q67440680 | ||
Claus K. Høgdall | Q67873804 | ||
Susan E. Hankinson | Q76570836 | ||
Ian Jacobs | Q77753455 | ||
Mark Sherman | Q88087477 | ||
Ellen L Goode | Q88243694 | ||
Beata Pepłońska | Q89284158 | ||
Thomas A Sellers | Q89445791 | ||
Anna H Wu | Q89864403 | ||
Daniel W. Cramer | Q90007566 | ||
Simon A Gayther | Q91677076 | ||
Honglin Song | Q91866986 | ||
Celeste Leigh Pearce | Q93009450 | ||
David V Conti | Q93010760 | ||
Michael E Carney | Q100738685 | ||
Edwin Severin Iversen, Jr. | Q102128502 | ||
Catherine M Phelan | Q109543723 | ||
Kathryn L Terry | Q109543794 | ||
Marc T Goodman | Q114258099 | ||
Andrew Berchuck | Q114258102 | ||
Galina Lurie | Q114314372 | ||
Patricia G Moorman | Q114314373 | ||
Valerie McGuire | Q114314375 | ||
Rebecca Sutphen | Q114314376 | ||
Brian Calingaert | Q114338156 | ||
Lydia Quaye | Q114340310 | ||
P2093 | author name string | Rebecca Anderson | |
Jeffrey R Marks | |||
Xiaoqing Chen | |||
David N Rider | |||
Merlise A Clyde | |||
Christopher K Elund | |||
P2860 | cites work | Identification of a novel p53 functional domain that is necessary for efficient growth suppression | Q24311276 |
The International HapMap Project | Q27860695 | ||
Meta-analysis in clinical trials | Q27860779 | ||
Haploview: analysis and visualization of LD and haplotype maps | Q27860955 | ||
Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer | Q28220263 | ||
Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium | Q29615642 | ||
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics | Q33330850 | ||
Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer | Q33833595 | ||
Two polymorphic variants of wild-type p53 differ biochemically and biologically | Q33868530 | ||
Regulation and function of the p53 tumor suppressor protein | Q34245385 | ||
Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk | Q34345107 | ||
A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors | Q35041315 | ||
Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer | Q35828653 | ||
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations | Q36641252 | ||
Consortium analysis of 7 candidate SNPs for ovarian cancer | Q37155532 | ||
P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. | Q38445136 | ||
An intron binding protein is required for transformation ability of p53. | Q40506598 | ||
Primary structure polymorphism at amino acid residue 72 of human p53. | Q40658642 | ||
TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. | Q42858445 | ||
Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. | Q44095287 | ||
Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. | Q44241453 | ||
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup | Q44551246 | ||
Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. | Q45984954 | ||
Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study | Q46151255 | ||
The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. | Q46184871 | ||
Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. | Q50545565 | ||
Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study. | Q50574501 | ||
Common variants in mismatch repair genes and risk of invasive ovarian cancer. | Q53345077 | ||
Germline polymorphism of p53 codon 72 in gynecological cancer. | Q54642739 | ||
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. | Q54685505 | ||
P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. | Q54761008 | ||
p53 polymorphism in ovarian and breast cancer | Q70994813 | ||
Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors | Q71610700 | ||
p53 polymorphism in ovarian and bladder cancer | Q71852144 | ||
Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study | Q79150763 | ||
A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer | Q80244055 | ||
Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer | Q81101652 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | ovarian cancer | Q172341 |
single-nucleotide polymorphism | Q501128 | ||
P304 | page(s) | 2349-2357 | |
P577 | publication date | 2009-03-10 | |
P1433 | published in | Cancer Research | Q326097 |
P1476 | title | Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer | |
P478 | volume | 69 |
Q33747778 | A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. |
Q34278861 | A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). |
Q82866392 | Advances in ovarian cancer disease control |
Q33553322 | Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer |
Q36586393 | Association of common WRAP 53 variant with ovarian cancer risk in the Polish population |
Q34416368 | BAYESIAN MODEL SEARCH AND MULTILEVEL INFERENCE FOR SNP ASSOCIATION STUDIES |
Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
Q37657957 | Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer |
Q36246404 | Downregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome |
Q36487146 | Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk |
Q33422082 | Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer |
Q34955369 | Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk |
Q37074094 | Genetics and women's health issues--the commitment of EMS to women scientists and gender-associated disease topics |
Q35058278 | Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer |
Q36718113 | Global ovarian cancer health disparities |
Q89582929 | Identifying multi-hit carcinogenic gene combinations: Scaling up a weighted set cover algorithm using compressed binary matrix representation on a GPU |
Q53089359 | Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk. |
Q49216581 | No association between TP53 Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects. |
Q34043691 | On the road with WRAP53β: guardian of Cajal bodies and genome integrity |
Q58767113 | Oncogenic Activity of Wrap53 in Human Colorectal Cancer In Vitro and in Nude Mouse Xenografts |
Q37446726 | Overexpression of WDR79 in non-small cell lung cancer is linked to tumour progression |
Q35120227 | Overexpression of WRAP53 is associated with development and progression of esophageal squamous cell carcinoma |
Q42356676 | Overexpression of the scaffold WD40 protein WRAP53β enhances the repair of and cell survival from DNA double-strand breaks |
Q33891803 | Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium |
Q35632374 | Polymorphisms in TP53 are associated with risk and survival of osteosarcoma in a Chinese population |
Q33829340 | Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotype |
Q33527422 | Risk of ovarian cancer and inherited variants in relapse-associated genes |
Q37996440 | Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). |
Q51800031 | Single-strand conformational polymorphism analysis of a common single nucleotide variation in WRAP53 gene, rs2287499, and evaluating its association in relation to breast cancer risk and prognosis among Iranian-Azeri population. |
Q35076240 | TP53 genetic polymorphisms, interactions with lifestyle factors and lung cancer risk: a case control study in a Chinese population |
Q33967373 | Telomerase Cajal body protein 1 depletion inhibits telomerase trafficking to telomeres and induces G1 cell cycle arrest in A549 cells |
Q35804614 | The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer |
Q34775177 | The inherited genetics of ovarian and endometrial cancer |
Q38806266 | The proximity ligation assay reveals that at DNA double-strand breaks WRAP53β associates with γH2AX and controls interactions between RNF8 and MDC1. |
Q34697751 | The scaffold protein WRAP53β orchestrates the ubiquitin response critical for DNA double-strand break repair |
Q34099786 | Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer |
Q34340254 | WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients |
Q30499635 | WRAP53 promotes cancer cell survival and is a potential target for cancer therapy |
Q39017292 | Women who deliver twins are more likely to smoke and have high frequencies of specific SNPs: Results from a sample of African-American women who delivered preterm, low birth weight babies. |
Q34177267 | Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk |
Search more.